IL1B and type 2 diabetes mellitus: Previous studies reported that active immunization by the peptide regions of mIL-1β resulted in significant high levels of autoantibodies against the native mIL-1β and showed protective effects against inflammation and collagen-induced arthritis in mice [28], indicating that the IL-1β-targeted vaccine may provide these advantages to treat T2DM patients.